Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive, metastatic, and clinically challenging breast cancer subtype with worst prognosis. Despite survival dependency on the proteasome pathway genes, the FDA-approved proteasome inhibitors induced minimal cli...
Multiplex substrate profiling by mass spectrometry obtained from the cleavage of Nf20S under presence of marizomib after time zero (T0, 4 replicates) and time 240minutes (T240, 4 replicates).
